M. Pranzatelli

发表

Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping.

B. Bielekova, M. Pranzatelli, 2017, Seminars in pediatric neurology.

Effect of Antiepileptic and Antimyoclonic Drugs on Serotonin Receptors in vitro

M. Pranzatelli, 1988, Epilepsia.

Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues.

A. Pestronk, A. Connolly, S. Mehta, 1997, The Journal of pediatrics.

Rituximab, IVIg, and Tetracosactide (ACTH1–24) Combination Immunotherapy (“RITE-CI”) for Pediatric Opsoclonus-Myoclonus Syndrome: Immunomarkers and Clinical Observations

M. Pranzatelli, M. Alber, L. Blumkin, 2017, Neuropediatrics.

Treatment of Infantile Spasms

J. Swann, M. Cortez, S. Shinnar, 2011, Journal of child neurology.

Pediatric Dosing of Rituximab Revisited: Serum Concentrations in Opsoclonus-myoclonus Syndrome

S. Bertolone, S. Verhulst, M. Pranzatelli, 2010, Journal of pediatric hematology/oncology.

On the Molecular Mechanism of Adrenocorticotrophic Hormone in the CNS: Neurotransmitters and Receptors

M. Pranzatelli, 1994, Experimental Neurology.

Effect of low-dose cyclophosphamide, ACTH, and IVIG combination immunotherapy on neuroinflammation in pediatric-onset OMS: A retrospective pilot study.

M. Pranzatelli, E. Tate, T. Allison, 2018, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

Long-Term Cerebrospinal Fluid and Blood Lymphocyte Dynamics After Rituximab for Pediatric Opsoclonus-Myoclonus

J. Colliver, M. Pranzatelli, E. Tate, 2009, Journal of Clinical Immunology.

Insights on Chronic-Relapsing Opsoclonus-Myoclonus From a Pilot Study of Mycophenolate Mofetil

J. Taub, M. Pranzatelli, W. Mitchell, 2009, Journal of child neurology.

Rituximab (anti-CD20) Adjunctive Therapy for Opsoclonus-Myoclonus Syndrome

M. Pranzatelli, B. Greffe, J. Mantovani, 2006, Journal of pediatric hematology/oncology.

Immunologic and Clinical Responses to Rituximab in a Child With Opsoclonus-Myoclonus Syndrome

M. Pranzatelli, E. Tate, D. Longee, 2004, Pediatrics.

B- and T-cell markers in opsoclonus–myoclonus syndrome: Immunophenotyping of CSF lymphocytes

S. Verhulst, M. Nigro, M. Pranzatelli, 2004, Neurology.

B- and T-cell markers in opsoclonus–myoclonus syndrome

S. Verhulst, M. Nigro, M. Pranzatelli, 2004, Neurology.

CSF B‐cell expansion in opsoclonus‐myoclonus syndrome: A biomarker of disease activity

S. Verhulst, M. Pranzatelli, E. Tate, 2004, Movement disorders : official journal of the Movement Disorder Society.

Immunophenotype of Blood Lymphocytes in Neuroblastoma-Associated Opsoclonus-Myoclonus

M. Pranzatelli, R. Jasty, E. Tate, 2004, Journal of pediatric hematology/oncology.

Hypothalamic-Midbrain Dysregulation Syndrome: Hypertension, Hyperthermia, Hyperventilation, and Decerebration

S. Pavlakis, D. Vivo, D. D. De Vivo, 1991, Journal of child neurology.

Evidence for involvement of 5-HT2 and 5-HT1C receptors in the behavioral effects of the 5-HT agonist 1-(2,5-dimethoxy-4-iodophenyl aminopropane)-2 (DOI)

M. Pranzatelli, 1990, Neuroscience Letters.

Acute dyskinesias in young asthmatics treated with theophylline.

R. Albin, M. Pranzatelli, B. Cohen, 1991, Pediatric neurology.

Topical Review: Putative Neurotransmitter Abnormalities in Infantile Spasms: Cerebrospinal Fluid Neurochemistry and Drug Effects

M. Pranzatelli, 1994, Journal of child neurology.

Buspirone in progressive myoclonus epilepsy.

M. Pranzatelli, E. Tate, D. Franz, 1993, Journal of neurology, neurosurgery, and psychiatry.

CHAPTER F1 – Pathophysiology, Neurophysiology, and Pharmacology of Human Myoclonus

M. Pranzatelli, 2005 .

Controlled Pilot Study of Piracetam for Pediatric Opsoclonus–Myoclonus

M. Pranzatelli, E. Tate, I. Galvan, 2001, Clinical neuropharmacology.

Regional central serotonin receptor binding in rats treated chronically with high-dose 5-hydroxy-L-tryptophan

M. Pranzatelli, 2004, Experimental Brain Research.

Cerebrospinal fluid 5‐hydroxyindoleacetic acid and homovanillic acid in the pediatric opsoclonus‐myoclonus syndrome

S. Gospe, M. Pranzatelli, M. Noetzel, 1995, Annals of neurology.

Neuropharmacology of Progressive Myoclonus Epilepsy: Response to 5‐Hydroxy‐L‐Tryptophan

S. Ashwal, J. Bodensteiner, R. Haas, 1995, Epilepsia.

The proposed role of neurotransmitter receptors in the pathophysiology of human myoclonic disorders.

M. Pranzatelli, 1989, Medical hypotheses.

The neurobiology of the opsoclonus-myoclonus syndrome.

M. Pranzatelli, 1992, Clinical neuropharmacology.

Absence of tolerance to the excitatory effects of benzodiazepines: Clonazepam-evoked shaking behavior in the rat

M. Pranzatelli, M. Levy, A. Dollison, 1991, Pharmacology Biochemistry and Behavior.

Benzodiazepine-induced shaking behavior in the rat: Structure-activity and relation to serotonin and benzodiazepine receptors

M. Pranzatelli, 1989, Experimental Neurology.

The guinea pig myoclonic model: behavioral supersensitivity to 5-hydroxytryptophan induced by intracisternal 5,7-dihydroxytryptamine.

S. R. Snodgrass, M. Pranzatelli, S. Snodgrass, 1987, European journal of pharmacology.

Myoclonus in childhood.

M. Pranzatelli, 2003, Seminars in pediatric neurology.

B cell depletion therapy for new‐onset opsoclonus‐myoclonus

J. Colliver, S. Verhulst, M. Pranzatelli, 2010, Movement disorders : official journal of the Movement Disorder Society.

Monoaminergic effects of high‐dose corticotropin in corticotropin‐responsive pediatric opsoclonus‐myoclonus

D. Goldstein, M. Shevell, E. Goldstein, 1998, Movement disorders : official journal of the Movement Disorder Society.

The immunopharmacology of the opsoclonus-myoclonus syndrome.

M. Pranzatelli, 1996, Clinical neuropharmacology.

Brainstem serotonin receptors in the guinea pig: Implications for myoclonus

M. Pranzatelli, P. Tailor, Parisa Razi, 1993, Neuropharmacology.

Ontogeny of [125I]iodocyanopindolol-labelled 5-hydroxytryptamine1B-binding sites in the rat CNS

M. Pranzatelli, I. Galvan, 1994, Neuroscience Letters.

Modulation of brainstem 5-HT1C receptors by serotonergic drugs in the rat.

M. Pranzatelli, P. Tailor, P. T. Tailor, 1994, General pharmacology.

Regional differences in the ontogeny of 5-hydroxytryptamine-1C binding sites in rat brain and spinal cord

M. Pranzatelli, 1993, Neuroscience Letters.

Cerebrospinal fluid ACTH and cortisol in opsoclonus-myoclonus: effect of therapy.

M. Pranzatelli, M. Moxness, E. Tate, 2005, Pediatric neurology.

Use of 5,6- and 5,7-Dihydroxytryptamine to Lesion Serotonin Neurons

M. Pranzatelli, 1998 .

Plasticity and ontogeny of the central 5-HT transporter: effect of neonatal 5,7-dihydroxytryptamine lesions in the rat.

M. Pranzatelli, J. M. Martens, 1992, Brain research. Developmental brain research.

Neonatal 5,7-DHT lesions upregulate [3H]mesulergine-labelled spinal 5-HT1C binding sites in the rat

M. Pranzatelli, 1990, Brain Research Bulletin.

The functional significance of neonatal 5,7-dihydroxytryptamine lesions in thes rat: Response to selective 5-HT1A and 5-HT2, 1C agonists

M. Pranzatelli, A. Dollison, Huang Yung-yu, 1990, Brain Research Bulletin.

Baltic myoclonus and Crohn's disease.

M. Pranzatelli, E. Tate, 1993, Movement disorders : official journal of the Movement Disorder Society.

Expression of CXCR3 and its ligands CXCL9, ‐10 and ‐11 in paediatric opsoclonus–myoclonus syndrome

R. Ransohoff, S. Verhulst, M. Pranzatelli, 2013, Clinical and experimental immunology.

A controlled trial of 5-hydroxy-l-tryptophan for ataxia in progressive myoclonus epilepsy

M. Pranzatelli, E. Tate, I. Galvan, 1996, Clinical Neurology and Neurosurgery.

G to C transversion at a splice acceptor site causes exon skipping in the cystatin B gene.

M. Burmeister, M. Pranzatelli, I. Bespalova, 1997, Mutation research.

Motor habituation in the DHT model: Bin analysis of daytime and nocturnal locomotor activity

S. R. Snodgrass, M. Pranzatelli, S. Snodgrass, 1986, Pharmacology Biochemistry and Behavior.

6‐Mercaptopurine modifies cerebrospinal fluid T cell abnormalities in paediatric opsoclonus–myoclonus as steroid sparer

M. Pranzatelli, E. Tate, T. Allison, 2017, Clinical and experimental immunology.

Neurometabolic effects of ACTH on free amino compounds in opsoclonus-myoclonus syndrome.

M. Creer, M. Pranzatelli, E. Tate, 2008, Neuropediatrics.

Demographic, Clinical, and Immunologic Features of 389 Children with Opsoclonus-Myoclonus Syndrome: A Cross-sectional Study

M. Pranzatelli, E. Tate, N. McGee, 2017, Front. Neurol..

Forty‐one year follow‐up of childhood‐onset opsoclonus‐myoclonus‐ataxia: Cerebellar atrophy, multiphasic relapses, and response to IVIG

M. Kinsbourne, V. Caviness, M. Pranzatelli, 2002, Movement disorders : official journal of the Movement Disorder Society.

CCR4 Agonists CCL22 and CCL17 are Elevated in Pediatric OMS Sera: Rapid and Selective Down-Regulation of CCL22 by ACTH or Corticosteroids

R. Ransohoff, J. Colliver, M. Pranzatelli, 2013, Journal of Clinical Immunology.

Cytokines, cytokine antagonists, and soluble adhesion molecules in pediatric OMS and other neuroinflammatory disorders

J. Colliver, M. Pranzatelli, E. Tate, 2013, Journal of the Neurological Sciences.

Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia.

Philip J. Holt, S. Kotagal, M. Griebel, 2002, Pediatric neurology.

Purkinje cell cytoplasmic antibody type 1 (anti-Yo) autoimmunity in a child with Down syndrome.

V. Lennon, M. Pranzatelli, S. Clardy, 2014, JAMA neurology.

Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome.

J. Colliver, M. Pranzatelli, E. Tate, 2008, Cytokine.

Cerebrospinal fluid oligoclonal bands in childhood opsoclonus-myoclonus.

J. Colliver, M. Pranzatelli, P. Slev, 2011, Pediatric neurology.

Going with the flow: neuroinflammation

M. Pranzatelli, 2011, Developmental medicine and child neurology.

Chemokine/cytokine profiling after rituximab: reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS.

S. Verhulst, M. Pranzatelli, E. Tate, 2011, Cytokine.

CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders

S. Verhulst, M. Pranzatelli, E. Tate, 2014, Journal of Neuroimmunology.

BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy

R. Ransohoff, J. Colliver, J. Ness, 2013, Journal of Neuroinflammation.

Treatment of Infantile Spasms: Emerging Insights From Clinical and Basic Science Perspectives

J. Swann, M. Cortez, S. Shinnar, 2011 .

CCR7 signaling in pediatric opsoclonus-myoclonus: upregulated serum CCL21 expression is steroid-responsive.

R. Ransohoff, M. Pranzatelli, E. Tate, 2013, Cytokine.

An unusual presentation of anti‐Hu‐associated paraneoplastic limbic encephalitis

H. Goodkin, N. Fountain, E. Thiele, 2012, Developmental medicine and child neurology.

Evaluation of Responsiveness to Reduced-Dose Rituximab in Corticotropin/Intravenous Immunoglobulin/Rituximab Combination Immunotherapy for Opsoclonus-Myoclonus Syndrome.

C. MacArthur, M. Pranzatelli, E. Tate, 2018, Pediatric neurology.

Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome

M. Pranzatelli, E. Tate, 2016, Brain and Development.

Acquired ataxias, infectious and para-infectious.

M. Pranzatelli, L. Blumkin, 2012, Handbook of clinical neurology.

Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS

R. Ransohoff, J. Colliver, J. Ness, 2012, Journal of Neuroimmunology.

Active Comparator-Controlled, Rater-Blinded Study of Corticotropin-Based Immunotherapies for Opsoclonus-Myoclonus Syndrome

S. Markwell, W. Lo, S. Verhulst, 2012, Journal of child neurology.

Infantile spasms versus myoclonus: is there a connection?

M. Pranzatelli, 2002, International review of neurobiology.

Oral Pharmacotherapy for the Movement Disorders of Cerebral Palsy

M. Pranzatelli, 1996, Journal of child neurology.

Topical Review: Antidyskinetic Drug Therapy for Pediatric Movement Disorders

M. Pranzatelli, 1996 .

Antimyoclonic properties of S2 serotonin receptor antagonists in the rat

S. R. Snodgrass, M. Pranzatelli, S. Snodgrass, 1986, Neuropharmacology.

NEUROBEHAVIORAL AND PSYCHOSOCIAL FUNCTIONING OF CHILDREN WITH OPSOCLONUS‐MYOCLONUS SYNDROME

P. H. Papero, M. Pranzatelli, P. Glass, 1995, Developmental medicine and child neurology.

Regional central serotonin-2 receptor binding and phosphoinositide turnover in rats with 5,7-dihydroxytryptamine lesions

P. Butler, M. Pranzatelli, A. Barkai, 1990, Brain Research Bulletin.

ACTH binds to [3H]MK-801-labelled rat hippocampal NMDA receptors.

R. Trifiletti, M. Pranzatelli, 1992, European journal of pharmacology.

The regulation of TRH and serotonin receptors: chronic TRH and analog administration in the rat.

M. Pranzatelli, A. Dailey, S. Markush, 1988, Journal of receptor research.

High-dose clonidine motor syndrome: Relationship to serotonin syndrome

S. R. Snodgrass, M. Pranzatelli, L. Schultz, 1987, Behavioural Brain Research.

Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines

M. Pranzatelli, 2018, Front. Immunol..

Characteristics and pharmacodynamics of severe neuroinflammation in a child with neurolupus

M. Pranzatelli, N. McGee, Zeng‐Yu Wang, 2016, Neurology: Neuroimmunology & Neuroinflammation.

Characterization of 5-hydroxytryptamine 1A-like binding sites in human ganglioneuroblastoma

M. Pranzatelli, J. Balletti, 1991, Neuroscience Letters.

Unstable insertion in the 5′ flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1

J. Rommens, F. Andermann, J. Janszky, 1997, Nature Genetics.

Chloral hydrate for progressive myoclonus epilepsy: a new look at an old drug.

M. Pranzatelli, E. Tate, 2001, Pediatric neurology.

Pediatric reference ranges for proinflammatory and anti-inflammatory cytokines in cerebrospinal fluid and serum by multiplexed immunoassay.

J. Colliver, M. Pranzatelli, E. Tate, 2013, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

A forward look at therapy for pediatric movement disorders.

M. Pranzatelli, 2003, Seminars in pediatric neurology.

Evidence of Cellular Immune Activation in Children With Opsoclonus-Myoclonus: Cerebrospinal Fluid Neopterin

G. Soori, M. Pranzatelli, E. Tate, 2004, Journal of child neurology.

Multifactorial analysis of opsoclonus‐myoclonus syndrome etiology (“Tumor” vs. “No tumor”) in a cohort of 356 US children

M. Pranzatelli, E. Tate, N. McGee, 2018, Pediatric blood & cancer.

Intensive Combination Immunotherapy and Neuroinflammation Resolution in a Child With Anti-PCA-1 (Yo) Paraneoplastic Syndrome and 2 Malignancies

M. Pranzatelli, E. Tate, G. Philipps, 2018, Child neurology open.

Encephalopathy with parkinsonian features in children following bone marrow transplantations and high‐dose amphotericin B

R. Packer, S. Mott, J. Conry, 1995, Annals of neurology.

Clinical spectrum of secondary parkinsonism in childhood: a reversible disorder.

S. Pavlakis, S. Mott, J. Conry, 1994, Pediatric neurology.

Serotonin-lesion Myoclonic syndromes. I. Neurochemical profile and S-1 receptor binding

S. R. Snodgrass, M. Pranzatelli, G. Rubin, 1986, Brain Research.

Brainstem serotonergic hyperinnervation modifies behavioral supersensitivity to 5-hydroxytryptophan in the rat.

M. Pranzatelli, A. Dollison, Y. Huang, 1989, Brain research. Developmental brain research.

Serotonin and human myoclonus. Rationale for the use of serotonin receptor agonists and antagonists.

M. Pranzatelli, Michael R. Pranzatelli, 1994, Archives of neurology.

Antibodies to ACTH in opsoclonus-myoclonus.

W. Dobyns, M. Chez, M. Pranzatelli, 1993, Neuropediatrics.

Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone.

M. Pranzatelli, E. Tate, M. Flint, 2005, The Journal of pediatrics.

The relation of central 5-HT1A and 5-HT2 receptors: Low dose agonist-induced selective tolerance in the rat

M. Pranzatelli, R. Pluchino, 1991, Pharmacology Biochemistry and Behavior.

Paraneoplastic syndromes: an unsolved murder.

M. Pranzatelli, 2000, Seminars in pediatric neurology.

Opsoclonus/Myoclonus and Neuroblastoma

M. Pranzatelli, 2009 .

Cortical tremor

M. Hallett, C. Toro, G. Deuschl, 1993, Neurology.

Chronic ACTH treatment increases striatal dopamine D-2 receptor binding in developing rat brain

D. Vivo, C. Chiriboga, M. Pranzatelli, 1989, Brain and Development.

Chronic ACTH treatment: Influence on 5-HT2 receptors and behavioral supersensitivity induced by 5,7-dihydroxytryptamine lesions

M. Pranzatelli, Brian Eng, 1989, Peptides.

Harmala alkaloids and related β-carbolines: A myoclonic model and antimyoclonic drugs

M. Pranzatelli, S.Robert Snodgrass, S. Snodgrass, 1987, Experimental Neurology.

3-acetylpyridine lesions and four serotonergic behavioral syndromes in the rat

M. Pranzatelli, S.Robert Snodgrass, Cathie Gantner, 1987, Brain Research Bulletin.

Ofatumumab for a rituximab‐allergic child with chronic‐relapsing paraneoplastic opsoclonus–myoclonus

M. Pranzatelli, S. Shenoy, E. Tate, 2012, Pediatric blood & cancer.

Drug-Induced Regulation of [125I]Iodocyanopindolol-labeled 5-Hydroxytryptamine1B Receptor Binding Sites in the Central Nervous System

M. Pranzatelli, Parisa Razi, 1994, Neuropsychopharmacology.

Brainstem 5-hydroxytrytamine1A binding sites are not down-regulated by agonists which induce tolerance in the rat: myoclonus and other serotonergic behaviors.

M. Pranzatelli, J. N. Murthy, 1992, Journal of receptor research.

Dissociation of the plasticity of 5-HT1A sites and 5-HT transporter sites

M. Pranzatelli, 1994, Neurochemical Research.

The pharmacology of myoclonus.

S. R. Snodgrass, M. Pranzatelli, 1985, Clinical neuropharmacology.

Regional glycine receptor binding in the p,p′-DDT myoclonic rat model

M. Pranzatelli, Katie Tkach, 2006, Archives of Toxicology.

Serotonin receptor ontogeny: Effects of agonists in 1-day-old rats

M. Pranzatelli, 1992, Pharmacology Biochemistry and Behavior.

Serotonin receptors in human neuroblastoma: A possible biologic tumor marker

M. Pranzatelli, J. Balletti, 1992, Experimental Neurology.

Novel regulation of 5-HT1C receptors: down-regulation induced both by 5-HT1C/2 receptor agonists and antagonists.

M. Pranzatelli, P. Tailor, Jayaslmha N. Murthy, 1993, European journal of pharmacology.

Effects of 5-HT receptor subtype-selective drugs on locomotor activity and motor habituation in the DHT adult rat model

S. R. Snodgrass, M. Pranzatelli, E. Jappay, 1987, Pharmacology Biochemistry and Behavior.

Hypothalamic-Midbrain Dysregulation Syndrome

M. Pranzatelli, R. Baska, 1992, Journal of child neurology.

Management of Neurologic Complications

M. Pranzatelli, K. Kramer, 2005 .

Movement disorders in childhood.

M. Pranzatelli, 1996, Pediatrics in review.

The pharmacology of antimyoclonic drugs.

M. Pranzatelli, 1995, Clinical neuroscience.

Quantitative autoradiography of 5-hydroxytryptamine1A binding sites in rats with chronic neonatal 5,7-dihydroxytryptamine lesions.

M. Pranzatelli, A. Barkai, M. Durkin, 1994, Brain research. Developmental brain research.

Intracisternal 5,7-dihydroxytryptamine lesions in neonatal and adult rats: comparison of response to 5-hydroxytryptophan.

M. Pranzatelli, A. Dollison, V. Hlibczuk, 1989, Developmental neuroscience.

Miscellaneous movement disorders of childhood.

M. Pranzatelli, 1993, Pediatric annals.

Cerebrospinal fluid free choline in movement disorders of paediatric onset.

A. Bergin, K. Mack, M. Pranzatelli, 1998, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

The comparative pharmacology of the behavioral syndromes induced by TRH and by 5-HT in the rat.

M. Pranzatelli, 1988, General Pharmacology.

Serotonin-lesion myoclonic syndromes. II. Analysis of individual syndrome elements, locomotor activity and behavioral correlations

M. Pranzatelli, S. Snodgrass, 1986, Brain Research.

Relation of intrathecal oligoclonal band production to inflammatory mediator and immunotherapy response in 208 children with OMS

M. Pranzatelli, E. Tate, N. McGee, 2018, Journal of Neuroimmunology.

Review article Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome

M. Pranzatelli, E. Tate, 2016 .

Neuroimmunology of OMS and ANNA-1/anti-Hu paraneoplastic syndromes in a child with neuroblastoma

M. Pranzatelli, N. McGee, 2017, Neurology: Neuroimmunology & Neuroinflammation.

Cerebrospinal fluid γδ T cell frequency is age‐related: a case–control study of 435 children with inflammatory and non‐inflammatory neurological disorders

M. Pranzatelli, E. Tate, T. Allison, 2018, Clinical and experimental immunology.

CCR4 Agonists CCL22 and CCL17 are Elevated in Pediatric OMS Sera: Rapid and Selective Down-Regulation of CCL22 by ACTH or Corticosteroids

R. Ransohoff, J. Colliver, M. Pranzatelli, 2013, Journal of Clinical Immunology.

Case‐control, exploratory study of cerebrospinal fluid chemokines/cytokines and lymphocyte subsets in childhood Tourette syndrome with positive streptococcal markers

M. Pranzatelli, E. Tate, T. Allison, 2017, Cytokine.

Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome.

M. Pranzatelli, E. Tate, 2017, Pediatric neurology.

Response to Sharawat and Suther.

M. Pranzatelli, E. Tate, 2018, Pediatric Neurology.

Novel cystatin B mutation and diagnostic PCR assay in an Unverricht-Lundborg progressive myoclonus epilepsy patient.

M. Burmeister, S. Adkins, M. Pranzatelli, 1997, American journal of medical genetics.

Microglial/macrophage markers CHI3L1, sCD14, and sCD163 in CSF and serum of pediatric inflammatory and non-inflammatory neurological disorders: A case-control study and reference ranges

M. Pranzatelli, E. Tate, N. McGee, 2017, Journal of the Neurological Sciences.

Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.

M. Demitrack, A. Lackner, W. Tourtellotte, 1992, Brain : a journal of neurology.

Regulation of 5-HT2 receptors in rat cortex. Studies with a putative selective agonist and an antagonist.

M. Pranzatelli, 1991, Biochemical pharmacology.

Identification of spinal 5-HT1C binding sites in the rat: characterization of [3H]mesulergine binding.

M. Pranzatelli, J. N. Murthy, R. Pluchino, 1992, The Journal of pharmacology and experimental therapeutics.

Plastic responses of neonatal 5-hydroxytryptamine1B receptors to 5,7-dihydroxytryptamine lesions mapped by quantitative autoradiography

M. Pranzatelli, M. Durkin, Michael Farmer, 1996, International Journal of Developmental Neuroscience.

The metabolic consequences of experimental intraventricular hemorrhage

M. Pranzatelli, D. Stumpf, 1985, Neurology.

THE EFFECT OF PROPOFOL ON MYOCLONUS AND CEREBROSPINAL FLUID MONOAMINE METABOLITES IN CHILDREN WITH OPSOCLONUS-MYOCLONUS

M. Pranzatelli, E. Tate, R. Kaplan, 1994 .